Autoimmune Diseases  >>  Rixathon (rituximab biosimilar)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rixathon (rituximab biosimilar) / Kyowa Kirin, Sandoz
NCT01274182 / 2010-021184-32: GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Checkmark Data for rheumatoid arthritis
Jul 2020 - Jul 2020: Data for rheumatoid arthritis
Checkmark In RA
Jun 2017 - Jun 2017: In RA
Completed
1/2
312
US, Europe, RoW
GP2013, MabThera, EU-Rituximab, Rituxan, US-Rituximab
Sandoz, Novartis Pharmaceuticals
Rheumatoid Arthritis
01/16
11/16

Download Options